Phase 2 Alcohol Clinical Trials

105 recruitingPhase 2

What is a Phase 2 trial?

Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.

Showing 120 of 105 trials

Recruiting
Phase 2

Tirzepatide in MetALD

Alcohol Use DisorderMetabolic Alcohol-associated Liver Disease
National Institute on Alcohol Abuse and Alcoholism (NIAAA)120 enrolled1 locationNCT07046819
Recruiting
Phase 2

Semaglutide Therapy for Alcohol Reduction (STAR)

Alcohol Use DisorderAddiction
National Institute on Drug Abuse (NIDA)80 enrolled1 locationNCT06015893
Recruiting
Phase 2

Integrated Therapies for Alcohol Use in Alcohol-associated Liver Disease (ITAALD) Trial

Alcohol Associated Hepatitis
Samer Gawrieh216 enrolled6 locationsNCT07060638
Recruiting
Phase 1Phase 2

Intestinal Microbiota Transplant in Alcohol-Associated Liver Disease

CirrhosisAlcohol Use DisorderLiver Disease; Alcohol-Related
Virginia Commonwealth University80 enrolled2 locationsNCT05548452
Recruiting
Phase 2

Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)

Non-Alcoholic Fatty Liver DiseaseNon Alcoholic Steatohepatitis
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)104 enrolled1 locationNCT03884075
Recruiting
Phase 2

Study of Tirzepatide for Recovery and Alcohol Use Management

Alcohol Use Disorder (AUD)
Brigham and Women's Hospital20 enrolled2 locationsNCT06727331
Recruiting
Phase 2

RCT of Prenatal Choline Supplementation During Pregnancy to Mitigate Adverse Effects of Prenatal Alcohol Exposure

Fetal Alcohol Spectrum DisordersFetal Alcohol Syndrome
Wayne State University288 enrolled1 locationNCT04395196
Recruiting
Phase 2

A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH

Non-Alcoholic Fatty Liver DiseaseMetabolic Dysfunction-Associated Steatohepatitis
GlaxoSmithKline42 enrolled30 locationsNCT06920043
Recruiting
Phase 2

Neurobehavioral Mechanisms of Psilocybin-assisted Treatment for AUD

Alcohol Use Disorder
NYU Langone Health200 enrolled1 locationNCT06349083
Recruiting
Phase 2

Pharmaceutically-Enhanced Reinforcement for Reduced Alcohol and Smoking

Nicotine Use DisorderAlcohol Use Disorder (AUD)
Washington State University205 enrolled1 locationNCT05181891
Recruiting
Phase 1Phase 2

Ketamine for Combined Depression and Alcohol Use Disorder

DepressionAlcohol Use Disorder
University Hospital of North Norway34 enrolled1 locationNCT06090422
Recruiting
Phase 2

Donepezil and Cognitive Training for Alcohol Use Disorder (AUD)

Alcohol Use Disorder
VA Connecticut Healthcare System160 enrolled1 locationNCT05042102
Recruiting
Phase 2

Suvorexant for Treatment of AUD and PTSD

InsomniaPost Traumatic Stress Disorder (PTSD)Alcohol Use Disorder (AUD)
Pharmacotherapies for Alcohol and Substance Use Disorders Alliance76 enrolled2 locationsNCT06679062
Recruiting
Phase 1Phase 2

Suvorexant for Alcohol Use Disorder (AUD): Neural Mechanisms

Healthy VolunteersAlcohol Use Disorder (AUD)
National Institute on Alcohol Abuse and Alcoholism (NIAAA)180 enrolled1 locationNCT06484075
Recruiting
Phase 2Phase 3

Alcohol Use Disorder and Cannabidiol

Alcohol Use Disorder
University of Colorado, Denver180 enrolled1 locationNCT05613608
Recruiting
Phase 2

Phase 2 Study of Apremilast in Women and Men With Alcohol Use Disorder

Alcohol Use Disorder
Yale University80 enrolled1 locationNCT07029529
Recruiting
Phase 2Phase 3

MDMA-Assisted Therapy for Veterans With PTSD and Alcohol Use Disorder

Post Traumatic Stress DisorderAlcohol Use Disorder
VA Office of Research and Development80 enrolled2 locationsNCT07118839
Recruiting
Phase 2

Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States

CirrhosisCirrhosis, LiverCirrhosis Due to Hepatitis B+5 more
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)256 enrolled13 locationsNCT05832229
Recruiting
Phase 2

GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV

Cardiovascular Disease PreventionSmoking, CigaretteHIV+1 more
Vanderbilt University Medical Center200 enrolled1 locationNCT07221214
Recruiting
Phase 2

Digoxin In NASH (CODIN)

MASLDMASH - Metabolic Dysfunction-Associated SteatohepatitisFatty Liver Disease+5 more
Yale University144 enrolled2 locationsNCT06588699